Dr. Reddy's Laboratories Limited — Important, 23-01-2025: Financial Result Updates

Consolidated financial results show a solid performance for Dr. Reddy's Laboratories. For the quarter ended December 31, 2024, total revenue reached ₹83,586 crore, marking a 16% increase year-over-year and a 4% increase from the previous quarter. The growth was primarily driven by the newly acquired Nicotine Replacement Therapy (NRT) business and robust demand in the Global Generics segment.

Net profit for Q3FY25 was ₹14,133 crore, up 2% YoY, with earnings per share (EPS) at ₹16.96. This reflects improvements in operational efficiency and cost management, although there was a sequential dip due to integration costs associated with the NRT acquisition. Operating expenses increased due to heightened R&D efforts totaling ₹6,658 crore (8% of revenues), and SG&A expenses rose by 19% to ₹24,117 crore, attributed to investment in marketing and integration efforts.

The balance sheet remains healthy, with cash reserves of ₹64,198 crore, indicating good liquidity. Strategic focus areas include enhancing product offerings and penetrating emerging markets, causing a positive market sentiment overall. Given the solid fundamentals and expansion potential, the outlook suggests a favorable long-term investment perspective, suggesting a buy.